40
Participants
Start Date
December 16, 2015
Primary Completion Date
May 1, 2019
Study Completion Date
December 29, 2020
Pertuzumab
Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Trastuzumab
Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Stony Brook University Medical Center, Stony Brook
Temple Cancer Center; Oncology, Philadelphia
Associates in Oncology-Hematology, PC, Bethesda
University of Maryland Medical Center; Department of Neurology, Baltimore
University of Miami Hospital & Clinics, Miami
H. Lee Moffitt Cancer Center and Research Inst., Tampa
Mid Ohio Oncology Hematology;ZangMeister Center (West), Columbus
Allina Health System, Saint Paul
Methodist Hospital Research Institute, Houston
Huntsman Cancer Institute; University of Utah, Salt Lake City
Arizona Cancer Center, Tucson
City of Hope National Medical Center, Duarte
Stanford Cancer Institute, Stanford
Northwest Medical Specialties, PLLC, Tacoma
Northwestern University, Chicago
Dana Farber Cancer Inst., Boston
Lead Sponsor
Genentech, Inc.
INDUSTRY